Sarepta Therapeutics, Inc. SRPT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | -$248.39M-206% | ||
| $45.14M+1.4% | $44.52M-10.5% | $49.72M+21.0% | $41.08M+5.4% | $38.96M+3.3% | ||
| $111.37M-9.7% | $123.4M-13.7% | $143.06M-16.6% | $171.58M-7.3% | $185.04M+0.4% | ||
| -$267.05M-29.5% | -$206.25M-432% | -$38.79M-123% | $167.3M-40.4% | $280.57M+39.1% | ||
| $211.97M-33.7% | $319.57M-33.6% | $481.23M+2.7% | $468.75M-8.5% | $512.02M+29.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$5.33M+24.5% | -$7.06M— | —— | —— | —— | ||
| -$117.47M-263% | $72.05M— | —— | —— | —— | ||
| —— | —— | —— | -$55.09M+39.9% | -$91.66M— | ||
| —— | —— | —— | —— | —— | ||
| $60.4M-40.8% | $101.97M-25.3% | $136.46M-9.5% | $150.79M+1.8% | $148.16M+8.2% | ||
| —— | —— | —— | —— | $927.8M-15.6% | ||
| $172.23M-1.1% | $174.1M0.0% | $174.1M+128% | -$629.78M-44.1% | -$436.93M— | ||
| $6.64M-15.7% | $7.88M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.56M-77.2% | $20M0.0% | $20M+145% | -$44.88M-595% | -$6.46M— | ||
| -$180.57M-7.3% | -$168.34M-110% | -$80.15M-256% | $51.4M-55.4% | $115.14M-7.7% | ||
| —— | —— | —— | —— | -$186.42M-128% | ||
| $31.14M+109% | $14.91M+1.8% | $14.65M-2.7% | $15.06M-5.0% | $15.86M0.0% | ||
| $38.53M+2.4% | $37.63M+16.8% | $32.22M-7.1% | $34.69M+54.1% | $22.51M-0.3% | ||
| -$3.91M+26.1% | -$5.29M+54.8% | -$11.71M+44.7% | -$21.2M+28.8% | -$29.79M+26.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$117.47M-263% | $72.05M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $165.26M+33.3% | $123.94M+50.0% | $82.63M+100% | $41.31M— | ||
| —— | —— | —— | —— | —— | ||
| -$5.33M+24.5% | -$7.06M— | —— | —— | —— | ||
| $13.13M-5.9% | $13.95M-8.2% | $15.2M-5.9% | $16.16M+0.1% | $16.15M-0.1% | ||
| —— | —— | —— | -$245.82M-1.8% | -$241.39M— | ||
| $6.64M-15.7% | $7.88M— | —— | —— | —— | ||
| $294M-0.6% | $295.87M-74.5% | $1.16B-15.4% | $1.37B-12.3% | $1.57B-21.8% | ||
| —— | $0-100% | $17K-50.0% | $34K-33.3% | $51K-25.0% | ||
| $960K-77.0% | $4.17M+1.2% | $4.12M+17.3% | $3.51M+9.5% | $3.21M— | ||
| —— | $0-100% | $11.34M-50.0% | $22.67M-33.3% | $34.01M-25.0% | ||
| —— | $47.4M+33.3% | $35.55M+50.0% | $23.7M+100% | $11.85M— | ||
| —— | $21.08M+33.3% | $15.81M+50.0% | $10.54M+100% | $5.27M— | ||
| —— | —— | —— | —— | $49.04M+14.7% | ||
| —— | $12.27M+33.3% | $9.2M+50.0% | $6.14M+100% | $3.07M— | ||
| —— | —— | —— | —— | $40.32M+14.0% | ||
| $38.53M+2.4% | $37.63M+16.8% | $32.22M-7.1% | $34.69M+54.1% | $22.51M-0.3% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Sarepta Therapeutics, Inc. generate?
- Sarepta Therapeutics, Inc. (SRPT) generated -$871.4M in operating cash flow over the trailing twelve months.
- What is Sarepta Therapeutics, Inc.'s free cash flow?
- After $60.4M of capital expenditures, Sarepta Therapeutics, Inc.'s free cash flow was -$977.3M over the trailing twelve months, down 92.8% year over year.
- Where does Sarepta Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
